Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Ntrust-1: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with Autoimmune Disease
Yao, Q. P. (PI), Gabig, T. (CoPI), Jandl, T. (CoPI), Lan, F. (CoPI), Lee, C. (CoPI), Liu, S. (CoPI) & Schuster, M. (CoPI)
05/16/25 → 08/19/26
Project: Research
-
Ntrust-2: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy in Subjects with Immune-Mediated Diseases
Schuster, M. (PI), Gabig, T. (CoPI), Jandl, T. (CoPI), Lan, F. (CoPI), Lee, C. (CoPI) & Liu, S. (CoPI)
05/5/25 → 03/26/26
Project: Research
-
ICT-8 Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Patients Unfit for Standard Chemotherapy
Gabig, T. (CoPI), Lan, F. (CoPI), Schuster, M. (CoPI), Salman, H. (PI) & Kiner-Strachan, B. (CoPI)
10/27/17 → 08/2/19
Project: Research
-
A Phase 1/1b,Multicenter, Open-label, Dose Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Schuster, M. (PI), Gabig, T. (CoPI), Lan, F. (CoPI), Kiner-Strachan, B. (CoPI) & Salman, H. (CoPI)
Forma Therapeutics, Incorporated
10/19/17 → 08/21/19
Project: Research
-
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients 18 Years with Newly Diagnosed Acute Myeloid Leukemia unfit for Standard Induction Chemotherapy
Gabig, T. (CoPI), Lan, F. (CoPI), Schuster, M. (CoPI), Salman, H. (PI) & Kiner-Strachan, B. (CoPI)
09/28/17 → 07/23/19
Project: Research
Research output
- 14 Article
-
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial
Masarova, L., Reeves, B. N., El Chaer, F., Foltz, L., Tashi, T., Abu-Zeinah, G., Lucas, J., Halpern, A. B., Maze, D., Qin, A., Safah, H., Lan, F., O'Connell, C. L., Goel, S., Rein, L., Fang, B., How, J., Babu, S., Li, Z. & Cerquozzi, S. & 11 others, , 2025, In: Frontiers in Medicine. 12, 1548590.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Lin, K. W., Jares, A., Firor, A. E., Shuai, X., Salman, H., Golightly, M., Lan, F., Senzel, L., Leung, E. L., Jiang, X. & Ma, Y., Oct 1 2017, In: Leukemia. 31, 10, p. 2151-2160 10 p.Research output: Contribution to journal › Article › peer-review
Open Access170 Scopus citations -
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
Pinz, K. G., Yakaboski, E., Jares, A., Liu, H., Firor, A. E., Chen, K. H., Wada, M., Salman, H., Tse, W., Hagag, N., Lan, F., Leung, E. L. H., Jiang, X. & Ma, Y., 2017, In: Oncotarget. 8, 68, p. 112783-112796 14 p.Research output: Contribution to journal › Article › peer-review
Open Access91 Scopus citations -
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Chen, K. H., Wada, M., Firor, A. E., Pinz, K. G., Jares, A., Liu, H., Salman, H., Golightly, M., Lan, F., Jiang, X. & Ma, Y., 2016, In: Oncotarget. 7, 35, p. 56219-56232 14 p.Research output: Contribution to journal › Article › peer-review
Open Access105 Scopus citations -
Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
Pinz, K., Liu, H., Golightly, M., Jares, A., Lan, F., Zieve, G. W., Hagag, N., Schuster, M., Firor, A. E., Jiang, X. & Ma, Y., Mar 1 2016, In: Leukemia. 30, 3, p. 701-707 7 p.Research output: Contribution to journal › Article › peer-review
98 Scopus citations